The minimal response to BET inhibitors in the resistant cells suggest intrinsic resistance to BET inhibitors in CRC, this led us to investigate additional agents that could be combined with JQ1 to overcome this obstacle. This evidence concerns the gene DNER and colorectal carcinoma.